FibroGen, Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 38,636 shares of FibroGen stock in a transaction that occurred on Tuesday, October 17th. The shares were sold at an average price of $55.02, for a total value of $2,125,752.72. Following the sale, the chief executive officer now directly owns 3,176,861 shares in the company, valued at approximately $174,790,892.22. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of FibroGen, Inc (NASDAQ FGEN) traded up 3.14% during midday trading on Friday, hitting $55.90. The company’s stock had a trading volume of 495,089 shares. FibroGen, Inc has a 12-month low of $15.60 and a 12-month high of $60.15. The firm has a 50-day moving average of $53.48 and a 200 day moving average of $38.02. The firm’s market cap is $3.98 billion.
FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.01). FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. The company had revenue of $29.00 million during the quarter, compared to analyst estimates of $34.80 million. On average, equities research analysts predict that FibroGen, Inc will post ($1.81) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/10/27/thomas-b-neff-sells-38636-shares-of-fibrogen-inc-fgen-stock.html.
FGEN has been the topic of several recent analyst reports. Jefferies Group LLC reissued a “buy” rating and set a $75.00 target price on shares of FibroGen in a research note on Tuesday, September 12th. Goldman Sachs Group, Inc. (The) downgraded FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective on the stock. in a research note on Friday, July 21st. BidaskClub cut FibroGen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Mizuho started coverage on FibroGen in a report on Wednesday, October 4th. They set a “neutral” rating and a $61.00 price objective for the company. Finally, Stifel Nicolaus restated a “buy” rating and set a $80.00 price objective on shares of FibroGen in a report on Thursday, September 14th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $65.67.
Large investors have recently bought and sold shares of the business. Prudential Financial Inc. boosted its position in FibroGen by 9.6% in the 2nd quarter. Prudential Financial Inc. now owns 448,780 shares of the biopharmaceutical company’s stock valued at $14,496,000 after buying an additional 39,430 shares during the last quarter. FMR LLC boosted its position in FibroGen by 96.9% in the 2nd quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock valued at $107,753,000 after buying an additional 1,641,423 shares during the last quarter. Principal Financial Group Inc. boosted its position in FibroGen by 0.4% in the 1st quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock valued at $3,354,000 after buying an additional 504 shares during the last quarter. Citigroup Inc. boosted its position in FibroGen by 37.3% in the 2nd quarter. Citigroup Inc. now owns 40,046 shares of the biopharmaceutical company’s stock valued at $1,294,000 after buying an additional 10,876 shares during the last quarter. Finally, Teachers Advisors LLC boosted its position in FibroGen by 1.4% in the 1st quarter. Teachers Advisors LLC now owns 468,413 shares of the biopharmaceutical company’s stock valued at $11,546,000 after buying an additional 6,512 shares during the last quarter. 47.37% of the stock is owned by institutional investors.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.